Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
ComboMATCH comprises numerous clinical trials that will evaluate different drug combinations.
PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.
The blood test identifies biomarkers that could make patients eligible for targeted therapies.
PARP inhibitor delays disease progression for patients with harmful BRCA and related mutations.
The PARP inhibitor delayed disease progression by 20 months compared with a placebo.
PARP inhibitor delays disease progression when used after successful chemotherapy.
First targeted therapy may prolong survival of men with advanced prostate cancer.
The three studies tested Zejula, Lynparza and veliparib in women with newly diagnosed advanced ovarian cancer.
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
Researchers are interested in combining PARP inhibitors with immunotherapies for pancreatic and other cancers with defects in DNA repair.
An ongoing study is assessing pediatric and young adult cancers that did not respond to initial treatments.
Lynparza (olaparib) may become standard follow-up therapy for women with newly diagnosed ovarian cancer that has a BRCA mutation.
PARP inhibitor slowed disease progression in clinical study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.